Predicting life-changing drugs for patients with cancer Calico Biosystems is on a mission to help pharma companies create effective, affordable drugs faster to counter cancer multi-omics assay, computational modeling, drug efficacy prediction, combination therapy, and Cell and virus-based therapeutics' efficacy

542 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Accelerating drug discovery to transform patients' lives Effective 11/22/21, Acceleron Pharma Inc. is now a wholly-owned subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the United States and Canada) http://merck.com Biopharmaceuticals, Orphan Disease Therapeutics, Rare Diseases, and Serious Diseases

610 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Science in Translation - We put inspiration into practice, finding viable solutions to complex challenges. Our mission is to turn scientific breakthroughs into progress for patients. TRON is a non-profit research institute that pursues new diagnostics and drugs for the treatment of cancer and other diseases with a high medical need. We aim to bridge the gap between fundamental science at universities and market-oriented research in the pharmaceutical industry. We turn innovative scientific concepts into treatments ready for clinical testing, thereby accelerating the translation of discoveries into new diagnostics and therapies for patients. We focus our transdisciplinary competencies in genomics …

122 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Transforming science into drug success stories Established in 2014, 4P-Pharma is a clinical-stage biotech company dedicated to addressing serious diseases with significant unmet medical needs. Our goal is to bring first-in-class therapies to patients swiftly.​ Our core is a specialized R&D engine that enhances risk management and accelerates the development process, effectively cutting down on time, costs, and uncertainty.​ We focus on developing assets combining rapid time to market and solid intellectual property. Our strategy leverages cutting-edge clinical trial designs and expedited regulatory pathways to bring our therapies to those in need as quickly as possible. Translational research, Biotechnology, Pharmaceuticals, …

167 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

At MedInsights, we are dedicated to bringing optimized therapeutic options for patients suffering from rare diseases. Our internal drug repositioning engine, NexusRx, serves as a cornerstone for our discovery research, employing internal sets of proprietary algorithms to detect unknown and unforeseen relationships between disease-targets-drugs. This opens up preclinical validation opportunities which we perform in close partnerships with our academic collaborators. We envision to perform clinical trials and bring therapeutics from lab to bed side. Crunchbase profile: https://www.crunchbase.com/organization/medinsights-0569 Biotech, Data Science, and Healthcare

131 similar entities Type: Startup Activities: deeptech biotech Technologies: A.I. A.I. - Machine Learning Data Analytics

Rewriting the rules of drug creation Cellarity is fundamentally redesigning the way drugs are created. By shifting the focus from a single target to the underlying cellular dysfunction, the company unravels the complexity of disease biology to create medicines that are out of reach with the target-based drug discovery approach. Founded by Flagship Pioneering in 2017, Cellarity has developed a platform that utilizes proprietary AI models trained on over 30 million single cell transcriptomes to uncover novel actionable biology and create non-intuitive drug candidates in a vast array of diseases. The company currently has programs ongoing in several disease areas …

281 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. Synthetic Biology

Smarter Tech, Faster Therapies We are dedicated to advancing access to numerous technological innovations, elevating the quality, rigor, and reliability of clinical research rooted in the scientific method. Our commitment is to be instrumental in accelerating drug development, supporting pharmaceutical and biotechnology companies to bring therapies to patients swiftly and efficiently. AI, Machine Learning, Technology, Data, and Adaptive Clinical Trials

245 similar entities Type: Startup Activities: biotech deeptech Technologies: Data Analytics

Targeting the biology of aging Life Biosciences is dedicated to developing novel therapies to extend healthy human lifespan by targeting the biological causes of aging. Founded in 2017 and headquartered in Boston, MA, we are pursuing therapies targeting three molecular pathways that regulate the biology of aging: mitochondrial uncoupling, chaperone-mediated autophagy, and epigenetic reprogramming. Our platform approach enables us to develop medicines with the potential to prevent, treat, and/or reverse multiple aging-related diseases, each with critical unmet needs. Healthspan, Aging Research, Longevity Research, Biotechnology, Aging, Age-Related Diseases, and Biology of Aging

13 similar entities Type: Startup Activities: biotech deeptech silvertech

Integrated Drug Discovery | Drug Development | Contract Research Selvita is one of the largest preclinical contract research organizations in Europe, driven by a clear mission: to offer a comprehensive scope of services bridging the gap between early drug discovery and the clinical stage of drug development. biotechnology, pharmaceuticals, drug discovery, preclinical research, bioanalytical development services, bioinformatics, systems biology, proteins, genomics, proteomics, autoimmune disorders, regulatory studies, medicinal chemistry, agrochemical, industrial chemistry, and assay development&screening

504 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Science-driven efficacy Founded in 2010, Biomeostasis is a leading Preclinical CRO that offers in vivo research services in the fields of Metabolic, GastroIntestinal & Muscle-Wasting Diseases. For over 15 years, we have been assessing the Efficacy & Mechanisms of action of Health Products that address conditions such as Obesity, Diabetes, MASLD/MASH, Atherosclerosis, Binge-eating, IBD, Sarcopenia, Cachexia, Duchenne Muscular Dystrophy (DMD)... Complementary to our in vivo pharmacology services, we offer Histology and Omics enabling deciphering the efficacy and MoA of Health Products in the metabolic, GI and muscle-wasting spaces. Localisation : Marseille - France preclinical, obesity, diabetes, gastrointestinal disorders, tailor-made rodent …

2 similar entities Type: Startup Activities: deeptech

Neurotech & photomedicine REGEnLIFE is an innovative company developing cutting-edge therapy for neurodegenerative disorders. Our company supports a non-invasive medical approach based on physical sciences. Our mission is to develop innovative and responsible technologies to face up to medical challenges and public health needs. Our goal is to provide to healthcare professionals a technology able to alter the progression of neurodegenerative diseases, in order to improve the health and quality of life to promote a healthy aging process. Our technology consists in a novel medical device dedicated to people living with neurodegenerative diseases, specifically Alzheimer-type dementia. MedTech, NeuroTech, Neurophonic, Photonics, …

86 similar entities Type: Startup Activities: biotech deeptech healthtech manufacturing Technologies: Synthetic Biology

Leading preclinical CRO specializing in metabolic disorders. Physiogenex is a leading preclinical research organization (CRO) specializing in metabolic disorders such as diabetes, insulin resistance, obesity, fatty liver (NASH / NAFLD), dyslipidemia, atherosclerosis and cardiovascular complications. We provide: - Classical and proprietary diet-induced in vivo models - Innovative in-house techniques (RCT) and gold standard methods (glucose clamps with radiolabelled tracers, ...) - In vivo preclinical imaging services Our models and technologies are customized and we deliver unparalleled scientific expertise for R&D, preclinical development, post-marketing studies and drug repositioning. We provide both the biopharmaceutical and nutraceutical companies with optimal and reliable solutions …

56 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

A leading nationwide clinical research site network pursing life-changing therapies committed to better patient outcomes CenExel is a leading integrated, wholly owned, nationwide clinical research site network comprised of 18 Centers of Excellence in major metropolitan areas across the U. S. With 40+ years of experience, our Centers of Excellence deliver deep scientific expertise, premium data, operational efficiencies, and exceptional patient engagement to drive successful complex clinical trial outcomes. The world's most results-driven Pharma, Biotech, and Clinical Research Organizations trust our strategic approach and benefit from our collaboration and unified sites’ commitment to real world solutions. Rely on us to …

82 similar entities Type: SMB Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Boosting the body's ability to defend against the damage of aging Five Alarm Bio is a drug discovery company based in Cambridge, UK focusing on novel approaches to anti-aging, with broad potential therapeutic application. We are researching therapeutics that boost the body's ability to defend against the damage of aging.

64 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Science of certainty Founded in 2008, we are a biotech company with two primary areas of business: Preclinical contract research organization (CRO) services and proprietary early target and drug discovery programs. Our focus is the metabolic space (e.g. obesity, diabetes, MASH and gastrointestinal diseases), where we specialize in peptide chemistry, in vivo pharmacology, ex vivo assays, molecular pharmacology, histology, imaging, stereology, NGS (next generation sequencing) and bioinformatics. Gubra is an abbreviation for GUt and BRAin, the original key focus areas of our research and expertise. We work with some of the most interesting and loyal partners and customers from across …

80 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Therapeutics for the Diseases of Aging Immune therapy platform targeting Dark Genome antigens that contribute to aging, cancer, diabetes, and neurodegenerative diseases Oncology, Aging, Dark Genome, ALS, Diabetes, and Longevity

196 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Leading biotech in the development of innovative microbiome-based biotherapies YSOPIA Bioscience is a clinical-stage biotech company developing cutting-edge biotherapies based on the gut microbiome. Our goal is to bring safe & efficient solutions to patients with high unmet medical needs. Microbiome, Obesity, Gut modulator, Cardiometabolism, Cardiometabolic diseases, Microbiota, and Gut microbiota

198 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

A new hope for patients affected by Alzheimer’s disease CaSRevolution is a research company specialized in devising innovative therapies for neurodegeneration diseases We have discovered a new mechanism that explains the progression of Alzheimer’s Disease and identified a potential therapeutic approach biotech, neurodegeneration, startup, and alzheimer

112 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Innovation at the service of your health and well-being. Pharmaceutical company, R & AMP; D dedicated to the development and marketing of senolytic compounds, food supplements and aging medications, age -related degenerative diseases and cancer.

324 similar entities Type: SMB Activities: deeptech biotech healthtech Technologies: Synthetic Biology

Société de biotechnologie au stade clinique axée sur le développement de son principal candidat médicament, RUVEMBRI Biophytis SA is a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging. Our small molecules are aimed at stimulating biological resilience to stress during aging. Ruvembri - in regulatory and clinical phases - is our leading drug candidate is administered orally: • for the treatment of severe respiratory events related to COVID-19 following positive results in Phase 2/3 clinical study (COVA) • for the treatment of reduced mobility in elderly patients with …

59 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

We deliver data for life > Aliri is committed to solving industry challenges by bringing innovative bioanalysis and spatial solutions to biotech and pharma, as the complexity of the drug development landscape continues to rise. Our mission is to support our customers with bringing life-saving therapies to market with speed and agility. We are focused on providing pharma and biotech companies with bioanalysis lab, spatial bioanalysis, and spatial biology solutions that will bring unique, comprehensive data to enable strategic decision making for lead optimization and strengthen regulatory submissions. MALDI Imaging, ADME analysis, Mass Spectrometry Imaging, Preclinical services, Molecular Imaging, Biodistribution, …

156 similar entities Type: Startup Activities: deeptech biotech healthtech Technologies: Synthetic Biology

Innovating to Enhance Quality of Life Fitabeo Therapeutics is a clinical-stage specialty pharmaceutical company that develops and commercialises a differentiated portfolio of innovative medicines focusing on indications where existing treatments are inadequate for the target population. It deploys breakthrough technologies to develop medicines that enable patient autonomy, decentralise patient care and provide superior health outcomes. Oral Thin Films, Geriatrics, Paediatrics, Patient autonomy, Equitable Access, Innovative medicines, Medication adherence, Central Nervous System, Women's Health, and Neurology

316 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Disruptive Therapies for Aging Diseases Topadur Pharma AG is a Swiss biopharmaceutical start-up based in Schlieren, Zurich. The company was founded in 2015 by experienced scientists that combine several years of expertise in R&D Pharma. Topadur’s vision is to improve patients’ quality of life by providing highly effective and safe drugs for unmet medical conditions. Topadur has discovered and developed new dual-acting drugs that target the cGMP-Enzyme Regulation System to stimulate microcirculation, enable tissue regeneration, and avoid local oxygen deficiency. Based on our key invention we have developed an attractive portfolio of drug candidates to treat aging-related diseases like chronic …

62 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We personalise prescribing by matching medication to patient data and DNA. Empowering doctors to say 'this drug is not for everyone, but it is for you. Founded in 2012, we are a London based start-up committed to personalising medicine. To achieve this, we've built a strong team with extensive expertise in pharmacogenetics, pharmacology, big data analytics, business strategy, the NHS and creative design. Pharmacogenetics, Personalised Medicine, Bioinformatics, CPOE, Big Data, and Design

78 similar entities Type: Startup Activities: healthtech biotech deeptech Technologies: Data Analytics

Galactica Biotech provides a drug repurposing method to identify novel applications for molecules in the market and in development for major and orphan diseases, reducing risk for patients and time and cost for companies. Our Mission With our specialized knowledge we are targeting to set new standards in the pharmaceutical industry adding value to old drugs and contributing to the health of people. Drug Discovery, Molecule characterization, Drug repurposing, and Novel compound applications

285 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. A.I. - Machine Learning Synthetic Biology

Building on innovative science to create treatments for patients in need ResoTher Pharma ApS is a biotechnology company focused on developing novel and effective peptide therapeutics for cardiovascular disease by targeting inflammation. Biotechnology, Drug Development, and Pharmaceutical Industry

657 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

AstronauTx is tackling dementia through improving brain physiology AstronauTx is at the forefront of a novel approach to treating neurodegenerative diseases. We have a unique portfolio of small-molecule therapeutics to restore dysregulated physiology to both improve symptoms and modify disease.

98 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

100% Natural Stability For Your Blood Sugar Levels and Weight With science-backed, 100% natural solutions, we empower journeys toward balanced and healthier lives by optimizing metabolism and making well-being achievable every day. prediabetes, diabetes, blood sugar management, healthtech, obesity, innovation, medical device, biotech, and life science

217 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Treating Neurodegenerative Disease by Restoring Autophagy At Samsara Therapeutics, we’re on a mission to unlock the full potential of autophagy activation in combating age-related neurodegenerative diseases. Our innovative approach aims to delay the progression of several debilitating conditions, offering new possibilities for patients and their families. biotechnology, biopharmaceuticals, rare disease, neurodegeneration, longevity, drug discovery, and drug development

159 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Better Technology. Better Delivery. Developing a new generation of disease-modifying therapies. Driven by our proprietary Enhanced Delivery Oligonucleotide (EDO) platform, we are creating a pipeline of disease-modifying therapeutics with the potential to safely and effectively target the root cause of serious genetic neuromuscular and neurological disorders. Biotechnology, Chemistry, Biology, Bioscience, Life sciences, and Therapeutics

435 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Target-led management of the causes of metabolic disease Diabetes currently effects over 537 million adults worldwide, with obesity-driven Type 2 Diabetes accounting for over 90% of cases. Dia Beta Labs build on over 30 years of high-impact research from our founding research group at Ulster University to realise the potential of next-generation therapeutics for metabolic disease. It is our goal to impart significant and much-needed change in the management of the global diabetes/obesity crisis. Diabetes, Peptide Development, Metabolic Disease, Obesity, and Peptide Therapeutics

19 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology